- Abstract Number: 2027
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
- Abstract Number: 0090
Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis
- Abstract Number: 0562
Large-Scale Targeted Sequencing Study Links Systemic Juvenile Idiopathic Arthritis with Rare Variants of MEFV, LYST, STXBP2, UNC13D
- Abstract Number: 1402
Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
- Abstract Number: 1482
Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
- Abstract Number: 1456
Latin-American Systemic Lupus Erythematosus Clusters
- Abstract Number: 0202
Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
- Abstract Number: PP08
Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
- Abstract Number: 1862
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
- Abstract Number: 1860
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
- Abstract Number: 0161
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
- Abstract Number: 1281
Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
- Abstract Number: 0824
Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis
- Abstract Number: 1698
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
- Abstract Number: 0226
Linguistics Biases in Letters of Recommendation Written for Rheumatology Fellowship Applicants
- Abstract Number: 2163
Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
- Abstract Number: 1963
Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population
- Abstract Number: 0254
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
- Abstract Number: PP19
Living with Rheumatoid Arthritis in a Rural Farming Community: How I Found a Rheumatologist and Got Targeted Treatment
- Abstract Number: 1559
Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines
- Abstract Number: 0890
Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort
- Abstract Number: 2056
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
- Abstract Number: 0644
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
- Abstract Number: 1578
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
- Abstract Number: 0408
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
- Abstract Number: 0806
Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
- Abstract Number: 2212
Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials
- Abstract Number: 0272
Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
- Abstract Number: 2111
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
- Abstract Number: 0470
Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
- Abstract Number: 1521
Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)
- Abstract Number: 0431
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
- Abstract Number: 2009
Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
- Abstract Number: 2191
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
- Abstract Number: 2121
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
- Abstract Number: 1636
Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort
- Abstract Number: 1652
Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
- Abstract Number: 0309
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
- Abstract Number: 0358
Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
- Abstract Number: 1042
Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
- Abstract Number: 0293
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
- Abstract Number: 1423
Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
- Abstract Number: 0355
Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
- Abstract Number: 0018
Longitudinal Development of Cartilage Microbial DNA Profiles Following Oral Microbiome Inoculation
- Abstract Number: 1407
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
- Abstract Number: 1088
Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
- Abstract Number: 0492
Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study
- Abstract Number: 0505
Longitudinal Trajectories of Central Pain Sensitization in People with or at Risk of Knee Osteoarthritis
- Abstract Number: 0360
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
- Abstract Number: 1869
Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
- Abstract Number: 0554
Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset
- Abstract Number: 0782
Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
- Abstract Number: 1027
Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis
- Abstract Number: 0693
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
- Abstract Number: 0165
Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis
- Abstract Number: 0976
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
- Abstract Number: 1318
Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
- Abstract Number: 0060
Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
- Abstract Number: 0270
Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
- Abstract Number: 2010
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
- Abstract Number: 1393
Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
- Abstract Number: 1569
Lung Involvement in VEXAS Syndrome
- Abstract Number: 1062
Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques
- Abstract Number: 1247
Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice
- Abstract Number: 2222
Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile
- Abstract Number: 0645
Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
- Abstract Number: 0183
LupusConnect™: A 24/7 Online Lupus Support Community
- Abstract Number: 1443
Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
- Abstract Number: 1439
Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
- Abstract Number: 0654
Lymphatic Dysfunction and Immune Activation in Lupus
- Abstract Number: 0830
Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis
ACR Convergence 2022
November 10-14, 2022. Philadelphia, PA.